1 / 1
Sparsentan(Filspari)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Travere Therapeutic
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Sparsentan, marketed as FILSPARI, is used for the management of primary IgAN, a condition that causes kidney damage. By antagonizing both endothelin type A and angiotensin II type 1 receptors, it helps to slow kidney function decline and reduce proteinuria in affected patients.
It is important for patients to undergo regular monitoring of liver function and to follow contraception guidelines due to the drug's risks of hepatotoxicity and embryo-fetal toxicity. Sparsentan offers a promising therapy for IgAN, but its use requires strict adherence to safety protocols to minimize the risk of adverse effects.
